Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lebrikizumab for Moderate to Severe Atopic Dermatitis
NCT04146363Phase 3Completed
- Sponsor
- Eli Lilly and Company
- Start
- Sep 2019
- Primary completion
- Jun 2021
- Modality
- Monoclonal Antibodies
- Countries
- 10
01
Overview
Phase 3, randomised, double-blind trial of lebrikizumab in atopic dermatitis (AD) (4 arms), sponsored by Eli Lilly and Company. Primary endpoints: Percentage of Participants With an Investigator Global Assessment (IGA) Score of 0 or 1 and a Reduction ≥2 Points at 16 weeks and Percentage of Participants Achieving ≥75% Reduction in Eczema Area And Severity Index (EASI-75) at 16 weeks. Started Sep 2019; status: completed.
02
Drugs
lebrikizumab
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT04146363.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04146363.